A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain
Open accessPublished version of a preprint
The DOI matches its Crossref record; 45 of the 48 references it cites were found in a registry or an index.
Abstract
A single dose of psilocybin, a psychedelic and serotonin 2A receptor (5-HT2AR) agonist, may be associated with antidepressant effects. The mechanism behind its antidepressive action is unknown but could be linked to increased synaptogenesis and down-regulation of cerebral 5-HT2AR. Here, we investigate if a single psychedelic dose of psilocybin changes synaptic vesicle protein 2A (SV2A) and 5-HT2AR density in the pig brain. Twenty-four awake pigs received either 0.08 mg/kg psilocybin or saline intravenously. Twelve pigs (n = 6/intervention) were euthanized one day post-injection, while the remaining twelve pigs were euthanized seven days post-injection (n = 6/intervention). We performed autoradiography on hippocampus and prefrontal cortex (PFC) sections with [3H]UCB-J (SV2A), [3H]MDL100907 (5-HT2AR antagonist) and [3H]Cimbi-36 (5-HT2AR agonist). One day post psilocybin injection, we observed 4.42% higher hippocampal SV2A density and lowered hippocampal and PFC 5-HT2AR density (−15.21% to −50.19%). These differences were statistically significant in the hippocampus for all radioligands and in the PFC for [3H]Cimbi-36 only. Seven days post-intervention, there was still significantly higher SV2A density in the hippocampus (+9.24%) and the PFC (+6.10%), whereas there were no longer any differences in 5-HT2AR density. Our findings suggest that psilocybin causes increased persistent synaptogenesis and an acute decrease in 5-HT2AR density, which may play a role in psilocybin’s antidepressive effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure A1 Saturation assay of [3H]UCB-J (a), [3H]MDL100907 (b) and [3H]Cimbi-36 (c) in the grey matter of the pig brain.](https://figures.cochat.ai/paper-figures/38d25f421ca64d38a1c3569974548753/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 1 Group-wise comparisons of synaptic vesicle protein 2A (SV2A) density (mean ± SD) in the hippocampus (a) and prefrontal cortex (PFC) (b) as measured with [3H]UCB-J autoradiography.](https://figures.cochat.ai/paper-figures/6f3973e6df5d483a8417e5831679ac65/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-1.jpg)
![Figure 2 Group-wise comparison of 5-HT2AR density (mean ± SD) as measured with [3H]MDL100907 and [3H]Cimbi-36 in the hippocampus (a,c) and PFC (b,d) using autoradiography.](https://figures.cochat.ai/paper-figures/aa078f12462a4e58b83778f85f9b47a1/a-single-dose-of-psilocybin-increases-synaptic-density-and-decreases-5-ht2a-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Psilocybin has also been shown to increase the density of SV2A in vivo as measured by PET imaging (155).”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“new imaging tools have the potential to identify biomarkers of psychoplastogen efficacy”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [155]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Using [3H]UCB-J in vitro autoradiography, we recently showed that a single administration of the 5-HT2A receptor agonist psilocybin was associated with higher hippocampal SV2A levels in awake pigs 24 h after administration [52].”
From Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial (2023) · cites this paper as [52]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638 · cited 2×
“Calibration, quantification and data evaluation was done using ImageJ software (NIH Image, Bethesda, MD, USA) [45].”
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“We investigate brain effects one day after psilocybin administration because the days following a psychedelic experience may provide a therapeutic window to treat mood disorders [6,7].”
InfluentialRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“A follow-up seven days after a psilocybin intervention is done because this is when depressive scores have been reported to be the lowest [6].”
InfluentialEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · cited 2×
“The increase in synaptic marker SV2A may result from the stimulation of the 5-HT2AR, TrkB and mTOR signalling pathways [10].”
Pompeiano, M., Palacios, J. M., & Mengod, G. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90223-2 · Cited by 881 · cited 1×
“More caution should be exerted when comparing the radioligands in hippocampus because the hippocampus has high levels of 5-HT2CR, with a density similar to 5-HT2AR [34,35] and [3H]Cimbi-36 also has affinity to 5-HT2CR [36,37].”
Decreased expression of synapse-related genes and loss of synapses in major depressive disorder
Kang, H. J., Voleti, B., Hajszan, T., Rajkowska, G., Stockmeier, C. A., Licznerski, P., Lepack, A., Majik, M. S., Jeong, L. S., Banasr, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2886 · Cited by 808 · cited 1×
“Both post-mortem human brain [14,15] and in vivo[16] studies in depressed individuals have shown a loss of synapses through the down-regulation of synaptic proteins and genes.”
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723
Cited by
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
The neural basis of psychedelic action
Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01177-4 · Cited by 302
Psilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 269
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
“Increased synaptic and dendritic density has been observed at 72 hours post-treatment in multiple studies [27, 37, 39].”
BackgroundResultNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
The promises and perils of psychedelic pharmacology for psychiatry
McClure-Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 194
Must Psilocybin Always “Assist Psychotherapy”?
Goodwin, G. M., Malievskaia, E., Fonzo, G. A., & Nemeroff, C. B. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20221043 · Cited by 189
Psychedelics and Other Psychoplastogens for Treating Mental Illness.
Vargas, M. V., Meyer, R., Avanes, A. A., Rus, M., & Olson, D. E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727117 · Cited by 166
Biochemical Mechanisms Underlying Psychedelic-Induced Neuroplasticity
Olson, D. E. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00812 · Cited by 129
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Rossi, R., Arjmand, S., Bærentzen, S. L., Gjedde, A., & Landau, A. M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.864514 · Cited by 123
Classic Psychedelic Drugs: Update on Biological Mechanisms
Vollenweider, F. X., & Smallridge, J. W. (2022) · Pharmacopsychiatry · doi:10.1055/a-1721-2914 · Cited by 128
Psychedelic therapy in the treatment of addiction: the past, present and future
Zafar, R. R., Siegel, M., Harding, R., Barba, T., Agnorelli, C., Suseelan, S., Roseman, L., Wall, M. B., Nutt, D. J., & Erritzøe, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1183740 · Cited by 125
“Interestingly, another study recently found SV2A to be upregulated in the pig brain 1 and 7 days after the pig was given a single psychedelic dose of psilocybin (176) which suggests a plausible restorative effect of psilocybin on pathological frontal plasticity.”
BackgroundCanalization and plasticity in psychopathology
Carhart-Harris, R. L., Chandaria, S., Erritzøe, D., Gazzaley, A. H., Girn, M., Kettner, H., Mediano, P. A. M., Nutt, D. J., Rosas, F. E., Roseman, L., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109398 · Cited by 114
Psilocybin facilitates fear extinction in mice by promoting hippocampal neuroplasticity
Du, Y., Li, Y., Zhao, X., Yao, Y., Wang, B., Zhang, L., & Wang, G. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002647 · Cited by 94
“[17,40] BDNF and mTOR signaling are crucial in fear extinction.”
BackgroundPsychedelics therapeutics: What we know, what we think, and what we need to research
Nutt, D., Spriggs, M., & Erritzoe, D. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109257 · Cited by 84
“In pigs psilocybin treatment has been shown to increase [3H]UCB-J density measured ex-vivo (Raval et al., 2021) and studies in humans are underway.”
Psychedelics and Neural Plasticity: Therapeutic Implications
Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022) · The Journal of Neuroscience · doi:10.1523/jneurosci.1121-22.2022 · Cited by 82
“Long-lasting changes in neural plasticity could potentially also be measured with functional imaging or SV2A PET ligands in humans (Raval et al., 2021; Knudsen, 2022).”
Self-citationPsychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
“Moreover, Knudsen and co- workers have used a UCB- J tracer to show that psilocybin increases SV2A density in pig cortex (Raval et al., 2021), offering the tantalizing possibility that SV2A density might serve as a translatable biomarker relevant to psychoplastogenic effects.”
BackgroundWeiss, F., Magnesa, A., Gambini, M., Gurrieri, R., Annuzzi, E., Elefante, C., Perugi, G., & Marazziti, D. (2025) · Brain Sciences · doi:10.3390/brainsci15020117 · Cited by 74
“…a statistically significant increase in a marker of synaptic density and plasticity (synaptic vesicle protein 2A, SV2A) and a decrease in 5-HT2A receptors both in the hippocampus and in the prefrontal cortex of pigs previously treated with 0.08 mg/kg intravenous psilocybin compared to placebo [52].”
InfluentialPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“In pigs, a single dose of psilocybin compared to saline resulted in 4% higher levels of hippocampal synaptic vesicle protein 2A (SV2A) and lowered hippocampal and PFC 5-HT2AR density (180).”
BackgroundPsilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 67
Imaging Synaptic Density: The Next Holy Grail of Neuroscience?
Serrano, M. E., Kim, E., Petrinovic, M. M., Turkheimer, F., & Cash, D. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.796129 · Cited by 67
“Importantly, although various studies often conflate synaptic density and synaptic function (Chen M.K. et al., 2021; Raval et al., 2021a; van Aalst et al., 2021), we must bear in mind that these two are different — although related — concepts that may sometimes lead to different results (see Figure…”
BackgroundOvercoming Depression with 5-HT2A Receptor Ligands
Zięba, A., Stępnicki, P., Matosiuk, D., & Kaczor, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010010 · Cited by 69
“These results suggest that psilocybin causes persistent synaptogenesis and a noticeable decline in 5-HT2A receptor density, which may be correlated with its antidepressant properties [71].”
BackgroundSustained effects of single doses of classical psychedelics in humans
Knudsen, G. M. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01361-x · Cited by 78
“In a small study of a heterogeneous group of patients with depressive symptoms, lower presynaptic binding in terms of SV2A was found in prefrontal cortex and hippocampus [46] and SV2A has also been found to be upregulated in the pig brain 1 and 7 days after the pig was given a single psychedelic dose of psilocybin [47…”
BackgroundSelf-citationRibarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Smausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 70
“For example, a single dose of psilocybin administration decreased 5HT2A-R levels in the mPFC and HC of pigs (Raval et al., 2021).”
BackgroundResultInfluentialAgnorelli, C., Spriggs, M. J., Godfrey, K., Sawicka, G., Bohl, B., Douglass, H. M., Fagiolini, A. M., Hashemi, P., Carhart-Harris, R. L., Nutt, D. J., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106132 · Cited by 68
“…in pigs after a single injection of a medium dose of psilocybin, showing higher synaptic density as measured via SV2A (measured via [ 3 H]-UCBJ post-mortem autoradiography) in the hippocampus 24 hours post-dose and higher SV2A in the hippocampus and PFC 7 days post-dose (Raval et al., 2021).”
Holze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 78
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 65
“These plasticity effects are consistent with studies in vitro [40, 41], as well in mouse hippocampus and in pigs [42, 43] and similar studies of related compounds [44, 45].”
ResultMolecular insights into psychedelic drug action
Slocum, S. T., DiBerto, J. F., & Roth, B. L. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15540 · Cited by 62
“In another paper, (Raval et al., 2021) administered a single dose of psilocybin to pigs, a higher species with a comparatively larger frontal cortex than rodents.”
BackgroundChen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
Revenga, M. D. L. F., Jaster, A. M., McGinn, J., Silva, G. M., Saha, S., & González‐Maeso, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00170 · Cited by 56
Johansen, A., Armand, S., Plavén-Sigray, P., Nasser, A., Ozenne, B., Petersen, I. N., Keller, S. H., Madsen, J., Beliveau, V., Møller, K., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02285-8 · Cited by 53
Self-citationThe Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
Skosnik, P. D., Sloshower, J., Safi-Aghdam, H., Pathania, S., Syed, S., Pittman, B., & D’Souza, D. C. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179800 · Cited by 51
“7 days after the administration of psilocybin (as measured via autoradiography and the tracer [3H]UCB-J, which assays changes in synaptogenesis via the synaptic vesicle protein 2A) (Raval et al., 2021).”
InfluentialKiilerich, K. F., Lorenz, J., Scharff, M. B., Speth, N., Brandt, T. G., Czurylo, J., Xiong, M., Jessen, N. S., Casado-Sainz, A., Shalgunov, V., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02280-z · Cited by 53
The role of neurotrophic factors in novel, rapid psychiatric treatments
Kim, J., He, M. J., Widmann, A. K., & Lee, F. S. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01717-x · Cited by 51
“In preclinical studies, psilocybin administration resulted in a persistent increase in dendritic spine density in mice [187], and persistent increases in synaptic density have been shown in pigs [188].”
BackgroundInserra, A., Campanale, A., Cheishvili, D., Dymov, S., Wong, A. H. Y., Marçal, N., Syme, R. A., Taylor, L., Gregorio, D. D., Kennedy, T. E., et al. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110594 · Cited by 47
Plazas, E., & Faraone, N. (2023) · Biomedicines · doi:10.3390/biomedicines11020461 · Cited by 47
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Urban, M. M., Stingl, M., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1156319 · Cited by 46
The structural diversity of psychedelic drug actions revealed
Gumpper, R. H., Jain, M. K., Kim, K., Sun, R., Sun, N., Xu, Z., DiBerto, J. F., Krumm, B. E., Kapolka, N. J., Kanıskan, H. Ü., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57956-7 · Cited by 46
Molecular and Functional Imaging Studies of Psychedelic Drug Action in Animals and Humans.
Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B. B., & Martin-Soelch, C. (2021) · Molecules · doi:10.3390/molecules26092451 · Cited by 43
Neuroimaging in psychedelic drug development: past, present, and future
Wall, M. B., Harding, R., Zafar, R. R., Rabiner, E. A., Nutt, D. J., & Erritzøe, D. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02271-0 · Cited by 46
CCH attack frequency reduction after psilocybin correlates with hypothalamic functional connectivity
Madsen, M. K., Petersen, A. S., Stenbæk, D. S., Sørensen, I. M., Schiønning, H., Fjeld, T., Nykjær, C. H., Larsen, S. M. U., Grzywacz, M. Z., Mathiesen, T., et al. (2024) · Headache The Journal of Head and Face Pain · doi:10.1111/head.14656 · Cited by 45
Self-citationShahar, O., Botvinnik, A., Shwartz, A., Lerer, E., Golding, P., Buko, A., Hamid, E., Kahn, D., Guralnick, M., Blakolmer, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02477-w · Cited by 40
The Effects of Psychedelics on Neuronal Physiology
Hatzipantelis, C. J., & Olson, D. E. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042022-020923 · Cited by 44
“In pigs, a single dose of psilocybin led to long-lasting increases in the presynaptic protein SV2A in both the PFC and hippocampus (76).”
Egger, K., Aicher, H., Cumming, P. D., & Scheidegger, M. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05353-6 · Cited by 46
“Neuroplasticity in response to ayahuasca or its constituents might be amenable to investigation by PET with a ligand for synaptic vesicle protein 2A (SV2A), as shown autoradiographically for the case of psilocybin in experimental animals [275].”
BackgroundFrom Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“…and psilocybin also show promise in treating both TRD and other mood disorders, as their agonism of the 5-HT 2A receptor primarily affects increased neuroplasticity, including synaptogenesis [70], neurogenesis [71], neurogenesis [72–75] and reconfiguration of brain network connectivity [76–79].”
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 48
“This might explain the rapid antidepressant effect observed in the clinical studies that have been conducted on psilocybin [129].”
BackgroundSerotonergic Psychedelics in Neural Plasticity
Łukasiewicz, K., Baker, J. J., Zuo, Y., & Lu, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.748359 · Cited by 39
“In the hippocampus and the PFC of pigs, a single dose of psilocybin also promotes synaptogenesis, as evidenced by a persistent increase in the presynaptic density of synaptic vesicle protein 2 (SV2A), a presynaptic integral glycoprotein that regulates neurotransmitter release (Raval et al., 2021).”
BackgroundPsilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Prouzeau, D., Conejero, I., Voyvodic, P. L., Bécamel, C., Abbar, M., & López‐Castromán, J. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01361-0 · Cited by 40
Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action
Rieser, N. M., Herdener, M., & Preller, K. H. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2021_284 · Cited by 37
Exploring mechanisms of psychedelic action using neuroimaging
Erritzøe, D., Timmermann, C., Godfrey, K., Castro-Rodrigues, P., Peill, J. M., Carhart-Harris, R. L., Nutt, D. J., & Wall, M. B. (2024) · Nature Mental Health · doi:10.1038/s44220-023-00172-3 · Cited by 42
“https://doi.org/10.1038/s44220-023-00172-3 cortex was observed one week after a single dose of psilocybin 124 .”
InfluentialPretargeted imaging beyond the blood–brain barrier
Shalgunov, V., van den Broek, S. L., Andersen, I. V., Vázquez, R. G., Raval, N. R., Palner, M., Mori, Y., Schäfer, G. G., Herrmann, B., Mikula, H., et al. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00360k · Cited by 39
Self-citationPepe, M., Hesami, M., de la Cerda, K. A., Perreault, M. L., Hsiang, T., & Jones, A. M. P. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108247 · Cited by 36
Human brain changes after first psilocybin use
Lyons, T., Spriggs, M. J., Kerkelä, L., Rosas, F. E., Roseman, L., Mediano, P. A. M., Timmermann, C., Oestreich, L., Pagni, B. A., Zeifman, R. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71962-3 · Cited by 41
“…work, this fi nding may be viewed as evidence of anatomical ‘ neuroplasticity ’ after fi rst-ever psychedelic use in humans, echoing earlier in-vivo animal studies following single-dose psilocybinthat reported increases in synaptic spine formation in female mice 5 and synaptic density in pigs 6 .”
Dourron, H. M., Strauss, C. K., & Hendricks, P. S. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000514 · Cited by 41
Wulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 41
“Psilocybin also results in increased synaptic density marker SV2A in pig hippocampus and prefrontal cortex (Raval et al., 2021).”
Impact of psilocybin on cognitive function: A systematic review
Meshkat, S., Tello-Gerez, T. J., Gholaminezhad, F., Dunkley, B. T., Reichelt, A. C., Erritzøe, D., Vermetten, E. H. G. J. M., Zhang, Y., Greenshaw, A. J., Burback, L., et al. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13741 · Cited by 36
Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
Garcia‐Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. B. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2021_267 · Cited by 36
“SV2A protein levels are thought to reflect presynaptic density, suggesting psilocybin may increase synaptogenesis up to a week after a single psilocybin exposure in pigs (Raval et al. 2021).”
BackgroundRossi, G. N., Guerra, L. T. L., Baker, G. B., Dursun, S. M., Bouso, J. C., Hallak, J. E. C., & SANTOS, R. G. D. (2022) · Biomolecules · doi:10.3390/biom12111618 · Cited by 40
A role for the serotonin 2A receptor in the expansion and functioning of human transmodal cortex
Luppi, A. I., Girn, M., Rosas, F. E., Timmermann, C., Roseman, L., Erritzøe, D., Nutt, D. J., Stamatakis, E. A., Spreng, R. N., Xing, L., et al. (2023) · Brain · doi:10.1093/brain/awad311 · Cited by 35
“30”
Psychedelics as preventive treatment in headache and chronic pain disorders
Schindler, E. A. D. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109166 · Cited by 31
Animal Behavior in Psychedelic Research
Odland, A. U., Kristensen, J. L., & Andreasen, J. T. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000590 · Cited by 32
Beating pain with psychedelics: Matter over mind?
Elman, I., Pustilnik, A. C., & Borsook, D. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.12.005 · Cited by 30
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
“, reported that the antidepressant effects of psilocybin were linked to increased formation of neuronal synapses and reduced expression of the serotonin 5-HT2A receptor [66].”
BackgroundWojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 30
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
“In recent studies, it is thought that this receptor downregulation triggers the formation of dendritic spine in presynaptic neuron, and thus, 5HT 2A agonists have a possible anti-psychotic effect by modulating synaptic plasticity (Raval et al., 2021).”
Díez-Alarcia, R., Muguruza, C., Rivero, G., García‐Bea, A., Gómez‐Vallejo, V., Callado, L. F., Llop, J., Martín, A., & Meana, J. J. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01430-7 · Cited by 30
The science of psychedelic medicine
Siegel, J. S., Liston, C. M., Nicol, G. E., Carhart-Harris, R. L., & Bogenschutz, M. P. (2026) · Nature Medicine · doi:10.1038/s41591-025-04194-5 · Cited by 28
“Initial attempts to measure psychedelic-induced increases in synaptic density with the positron emission tomography tracer 11 C-UCB-J have been inconsistent 86,87 .”
The mechanistic divide in psychedelic neuroscience: An unbridgeable gap?
Barksdale, B. R., Doss, M. K., Fonzo, G. A., & Nemeroff, C. B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00322 · Cited by 28
“These structural changes are not con fi ned to in vitro settings; they have been observed in ex vivo tissue samples and in the intact brain in vivo [46 – 48].”
BackgroundPsilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
“Additionally, it has been observed to increase the density of SV2A in the hippocampus and PFC of pig brains, indicating greater presynaptic density (Raval et al., 2021).”
BackgroundPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628
“Finally, in the pig, psilocybin administration was associated with higher binding of a presynaptic protein tracer in positron emission tomography (Raval et al., 2021).”
Do the therapeutic effects of psilocybin involve actions in the gut?
Reed, F. M., & Foldi, C. J. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.12.007 · Cited by 28
Erkizia-Santamaría, I., Horrillo, I., Martínez-Álvarez, N., Pérez-Martínez, D., Rivero, G., Erdozain, A. M., Meana, J. J., & Ortega, J. E. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03421-4 · Cited by 26
“It is reasonable to think that a closer time point would be more suitable for the evaluation of certain molecular pathways targeted by the drug, to unfold the molecular basis of the therapeutic action of psilocybin.”
Pretargeted Imaging beyond the Blood–Brain Barrier—Utopia or Feasible?
van den Broek, S. L., Shalgunov, V., Vázquez, R. G., Beschörner, N., Bidesi, N., Nedergaard, M., Knudsen, G. M., Sehlin, D., Syvänen, S., & Herth, M. M. (2022) · Pharmaceuticals · doi:10.3390/ph15101191 · Cited by 24
Self-citationPsychedelics action and schizophrenia
Maćkowiak, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00546-5 · Cited by 31
Šabanović, M., Lazari, A., Blanco-Pozo, M., Tisca, C., Tachrount, M., Martins-Bach, A. B., Lerch, J. P., Walton, M. E., & Bannerman, D. M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02439-2 · Cited by 28
Laabi, S., LeMmon, C., Vogel, C., Chacon, M., & Jimenez, V. M. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114940 · Cited by 23
Psilocybin’s Potential Mechanisms in the Treatment of Depression: A Systematic Review
Lee, H. J., Tsang, V. W. L., Chai, B. S., Lin, M. C., Howard, A. K., Uy, C. E., & Elefante, J. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2223195 · Cited by 22
“In the PFC, SV2A density remained unchanged and 5-HT2AR density was reduced one day after treatment; however, SV2A density was increased, with no change in 5-HT2AR from baseline after seven days (Raval et al. 2021).”
BackgroundResultInfluentialWang, S., Kim, S., Choi, W.-S., Lim, H. K., Woo, Y. S., Pae, C., & Bahk, W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1134 · Cited by 21
“It is rapidly metabolized in the body and acts as an agonist on various serotonin receptors, also known as 5-hydroxytryptamine (5-HT) receptors [18].”
BackgroundHaniff, Z. R., Bocharova, M., Mantingh, T., Rucker, J., Velayudhan, L., Taylor, D. M., Young, A. H., Aarsland, D., Vernon, A. C., & Thuret, S. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108641 · Cited by 22
Harari, R., Chatterjee, I., Getselter, D., & Elliott, E. (2024) · iScience · doi:10.1016/j.isci.2024.109686 · Cited by 21
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
Zeiss, R., Gahr, M., & Graf, H. (2021) · Pharmaceuticals · doi:10.3390/ph14100985 · Cited by 32
“Nevertheless, the same study demonstrated a higher hippocampal synaptic vesicle protein 2A density that remained significantly higher 7 days post-treatment, suggesting an increased persistent synaptogenesis [48].”
BackgroundResultCellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 24
Mind over matter: the microbial mindscapes of psychedelics and the gut-brain axis
Caspani, G., Ruffell, S., Tsang, W., Netzband, N., Rohani-Shukla, C., Swann, J. R., & Jefferies, W. A. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107338 · Cited by 21
“…• Enrichment-related cortical plasticity was abolished in antibiotic-treated mice, but could be normalised via a microbiota transfer from healthy donor mice [112] • Many psychedelic drugs promote LTP and stimulate the formation and growth of new synapses and dendrites [113,114,156,164,24, 48,49] 3.”
Psilocybin as a novel treatment for chronic pain
Askey, T., Lasrado, R., Maiarù, M., & Stephens, G. J. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17420 · Cited by 22
“…(1 mg kg (cid:1) 1 )-induced release of plasticity markers preceded a persistent increase in dendritic spine growth in the cortex (Ly et al., 2018; Shao et al., 2021), which has been associated with increased density of the presynaptic marker synaptic vesicle protein 2A (Raval et al., 2021).”
Köşeli, E., Buzzi, B., Honaker, T., Rakholia, Y., Lewis, M., Gaines-Smith, M., Jaster, A. M., González‐Maeso, J., & Damaj, M. I. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107699 · Cited by 18
“…pain models such as chronic inflammation, neuropathy and CIPN [23,24,25], it is possible that the single administration of psilocybin and/or DOI in our models reduce pain-like behaviors by decreasing 5-HT 2A R subtypes in the spinal cord and other brain regions as reported in animal studies [20].”
A qualitative analysis of the psychedelic mushroom come-up and come-down
Brouwer, A., Brown, J. K., Erowid, E., Erowid, F., Thyssen, S., Raison, C. L., & Carhart-Harris, R. L. (2025) · npj Mental Health Research · doi:10.1038/s44184-024-00095-6 · Cited by 19
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Tabaac, B. J., Shinozuka, K., Arenas, A., Beutler, B. D., Cherian, K. N., Evans, V. D., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001724 · Cited by 17
“22 Strengthening of excitatory synapses in both the mouse hippocampus and frontal cortex has been directly linked to the antidepressant effects of psilocy-bin.”
BackgroundSzafoni, S., Gręblowski, P., Grabowska, K., & Więckiewicz, G. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1406888 · Cited by 18
Effinger, D. P., Hoffman, J. L., Mott, S., Magee, S. N., Quadir, S. G., Rollison, C. S., Toedt, D., Sanchez, M. E., High, M. W., Hodge, C. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49741-9 · Cited by 17
An In Vivo High-Resolution Human Brain Atlas of Synaptic Density
Johansen, A., Beliveau, V., Colliander, E., Raval, N. R., Dam, V. H., Gillings, N., Aznar, S., Svarer, C., Plavén‐Sigray, P., & Knudsen, G. M. (2024) · Journal of Neuroscience · doi:10.1523/jneurosci.1750-23.2024 · Cited by 17
Self-citationCollins, S. M., O’Connell, C. J., Reeder, E. L., Norman, S. V., Lungani, K., Gopalan, P., Gudelsky, G. A., & Robson, M. J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.930346 · Cited by 17
“This includes decreases in detectable 5HT2A receptor densities and/or expression in cortical regions known to be involved in the actions of 5-HT2A receptor agonists (Raval et al., 2021).”
BackgroundKelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 17
“12-19 20-26 Considering the massive societal and economic burden of mental illness, the relative ineffectiveness of many current therapies and the transdiagnostic reach of psychedelics, the renewed interest in these plant and fungal medicines, and more recently discovered semi-synthetic and…”
BackgroundZhornitsky, S., Oliva, H. N. P., Jayne, L. A., Allsop, A. S., Kaye, A. P., Potenza, M. N., & Angarita, G. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1197890 · Cited by 17
“08 to 8 mg/kg, increased both PSD-95 and SV2A expression in the PFC and increased SV2A in the hippocampus (55, 58).”
BackgroundReligious and spiritual experiences from a neuroscientific and complex systems perspective
Jedlička, P., & Havenith, M. N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106319 · Cited by 16
“…2024) or a greater openness of personality (Knudsen, 2023) (but sometimes also serious adverse events, see (Hinkle et al., 2024)). r This observation means that psychedelics alter the brain persistently and induce long-term plasticity (Cameron et al., 2021; Raval et al., 2021; Shao et al., 2021).”
Neuroprotective effects of psilocybin in a rat model of stroke
Yu, S., Wu, K., Wang, Y.-S., Bae, E., Chianelli, F., Bambakidis, N. C., & Wang, Y. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00903-x · Cited by 16
“Both psilocybin and DMT [15] increased synaptic density [16], improved neuroplasticity [17, 18], and showed anti-depressant [19] activity in experimental animals.”
BackgroundUnblinding and demand characteristics in the treatment of depression
Goodwin, G. M., Croal, M., Marwood, L., & Malievskaia, E. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.030 · Cited by 15
Barnett (2024) · doi:10.1089/psymed.2023.0010 · Cited by 13
“…5-HT 2A receptors are known to readily internalize with both agonism and antagonism, 107 and psychedelics, as 5-HT 2A agonists or partial agonists, have been shown to cause both a transient downregulation of 5-HT 2A receptors 108 and a substantial slowing of the re-expression of these receptors.”
Tuominen, L. J., Armio, R.-L., Hansen, J. Y., Walta, M., Koutsouleris, N., Laurikainen, H., Salokangas, R. K. R., Mišić, B., & Hietala, J. A. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03336-0 · Cited by 13
Metadata
- Authors
- Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M.
- Affiliations
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- Harvard University (US)
- Corresponding author
- Hansen, Hanne Demant
- Knudsen, Gitte Moos
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-15
- Volume
- 22
- Issue
- 2
- Pages
- 835
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7830000
- OpenAlex
- W3108222140
- Cited by
- 200
- References
- 48
- Citations by year
- 2026: 31 · 2025: 38 · 2024: 40 · 2023: 41 · 2022: 33 · 2021: 17
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Preprints.org (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Funders
- Horizon 2020 (813528)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psilocybin, 5-HT2A receptor, synaptic density, synaptogenesis, SV2A, hippocampus, prefrontal cortex, antidepressant mechanism, psychedelics, pig brain, receptor down-regulation
- MeSH terms
- Animals, Antidepressive Agents, Autoradiography, Brain, Female, Hallucinogens, Hippocampus, Ligands, Psilocybin, Swine, Synapses, Prefrontal Cortex, Receptor, Serotonin, 5-HT2A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.